Sellas Life Sciences Group IncNASDAQ:SLS
- LAST PRICE1.1950
- TODAY'S CHANGE (%)0.0550 (4.8246%)
- Bid / Lots1.1900/ 24
- Ask / Lots1.2000/ 1
- Open / Previous Close1.1600 / 1.1400
- Day Range
- 52 Week Range
- Volume453,418
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLS |
|---|---|---|
| 09:32 ET | 1930 | 1.16 |
| 09:34 ET | 15090 | 1.1501 |
| 09:36 ET | 3539 | 1.14 |
| 09:38 ET | 640 | 1.14 |
| 09:39 ET | 6107 | 1.15 |
| 09:41 ET | 21352 | 1.1505 |
| 09:43 ET | 2923 | 1.15 |
| 09:45 ET | 1526 | 1.1499 |
| 09:48 ET | 873 | 1.14 |
| 09:50 ET | 100 | 1.14 |
| 09:54 ET | 1377 | 1.13 |
| 09:56 ET | 100 | 1.12 |
| 09:57 ET | 546 | 1.12 |
| 09:59 ET | 2885 | 1.12 |
| 10:01 ET | 435 | 1.12 |
| 10:03 ET | 4619 | 1.125 |
| 10:06 ET | 3398 | 1.13 |
| 10:12 ET | 1000 | 1.135 |
| 10:14 ET | 1100 | 1.1385 |
| 10:15 ET | 948 | 1.13 |
| 10:17 ET | 1600 | 1.135 |
| 10:19 ET | 1057 | 1.13 |
| 10:21 ET | 200 | 1.135 |
| 10:24 ET | 12666 | 1.13 |
| 10:26 ET | 7280 | 1.125 |
| 10:28 ET | 4750 | 1.1297 |
| 10:30 ET | 2667 | 1.125 |
| 10:33 ET | 189 | 1.13 |
| 10:35 ET | 200 | 1.1308 |
| 10:39 ET | 100 | 1.12 |
| 10:42 ET | 1400 | 1.12 |
| 10:44 ET | 11506 | 1.12 |
| 10:46 ET | 450 | 1.12 |
| 10:48 ET | 100 | 1.11 |
| 10:50 ET | 250 | 1.1199 |
| 10:51 ET | 300 | 1.11 |
| 10:55 ET | 7810 | 1.129 |
| 10:57 ET | 4100 | 1.12 |
| 11:00 ET | 5000 | 1.1201 |
| 11:02 ET | 600 | 1.12 |
| 11:04 ET | 112 | 1.12 |
| 11:06 ET | 11151 | 1.1199 |
| 11:08 ET | 7200 | 1.11 |
| 11:09 ET | 9994 | 1.115 |
| 11:11 ET | 15643 | 1.11 |
| 11:13 ET | 436 | 1.1 |
| 11:15 ET | 540 | 1.1001 |
| 11:18 ET | 5302 | 1.1005 |
| 11:20 ET | 5100 | 1.105 |
| 11:22 ET | 300 | 1.105 |
| 11:26 ET | 10589 | 1.115 |
| 11:27 ET | 3100 | 1.115 |
| 11:29 ET | 14828 | 1.12 |
| 11:31 ET | 1893 | 1.1201 |
| 11:33 ET | 200 | 1.12 |
| 11:36 ET | 399 | 1.1216 |
| 11:38 ET | 19595 | 1.125 |
| 11:40 ET | 22978 | 1.14 |
| 11:42 ET | 1000 | 1.1387 |
| 11:44 ET | 343 | 1.135 |
| 11:45 ET | 100 | 1.135 |
| 11:47 ET | 100 | 1.135 |
| 11:49 ET | 2500 | 1.13 |
| 11:51 ET | 100 | 1.14 |
| 11:56 ET | 300 | 1.1323 |
| 11:58 ET | 4100 | 1.1377 |
| 12:00 ET | 2298 | 1.1399 |
| 12:02 ET | 12920 | 1.155 |
| 12:03 ET | 8790 | 1.155 |
| 12:05 ET | 180 | 1.155 |
| 12:07 ET | 298 | 1.15 |
| 12:09 ET | 1100 | 1.16 |
| 12:12 ET | 7000 | 1.1661 |
| 12:14 ET | 900 | 1.155 |
| 12:16 ET | 1382 | 1.155 |
| 12:18 ET | 100 | 1.16 |
| 12:20 ET | 950 | 1.155 |
| 12:21 ET | 4366 | 1.15 |
| 12:23 ET | 1450 | 1.14 |
| 12:25 ET | 3030 | 1.145 |
| 12:27 ET | 930 | 1.15 |
| 12:30 ET | 500 | 1.1501 |
| 12:32 ET | 200 | 1.155 |
| 12:36 ET | 250 | 1.1521 |
| 12:38 ET | 750 | 1.1501 |
| 12:39 ET | 600 | 1.1501 |
| 12:41 ET | 2300 | 1.16 |
| 12:43 ET | 3800 | 1.155 |
| 12:45 ET | 100 | 1.155 |
| 12:48 ET | 600 | 1.1501 |
| 12:50 ET | 321 | 1.155 |
| 12:52 ET | 200 | 1.15 |
| 12:54 ET | 100 | 1.155 |
| 12:59 ET | 512 | 1.1523 |
| 01:01 ET | 3620 | 1.1597 |
| 01:06 ET | 100 | 1.155 |
| 01:08 ET | 100 | 1.16 |
| 01:12 ET | 100 | 1.155 |
| 01:14 ET | 862 | 1.1599 |
| 01:15 ET | 2100 | 1.1575 |
| 01:17 ET | 100 | 1.16 |
| 01:21 ET | 1564 | 1.152 |
| 01:28 ET | 100 | 1.155 |
| 01:33 ET | 2369 | 1.155 |
| 01:37 ET | 3100 | 1.155 |
| 01:39 ET | 1400 | 1.15 |
| 01:42 ET | 2000 | 1.155 |
| 01:46 ET | 5465 | 1.155 |
| 01:48 ET | 1456 | 1.155 |
| 01:53 ET | 1080 | 1.15 |
| 02:00 ET | 301 | 1.15 |
| 02:02 ET | 11994 | 1.1502 |
| 02:04 ET | 100 | 1.15 |
| 02:06 ET | 31005 | 1.175 |
| 02:11 ET | 178 | 1.1799 |
| 02:13 ET | 631 | 1.1718 |
| 02:20 ET | 821 | 1.17 |
| 02:22 ET | 872 | 1.175 |
| 02:24 ET | 250 | 1.17 |
| 02:27 ET | 200 | 1.18 |
| 02:31 ET | 550 | 1.18 |
| 02:36 ET | 18986 | 1.2 |
| 02:38 ET | 4790 | 1.2011 |
| 02:40 ET | 1890 | 1.2 |
| 02:42 ET | 105 | 1.205 |
| 02:44 ET | 4121 | 1.21 |
| 02:45 ET | 2443 | 1.1999 |
Jun 24, 2024
Jun 17, 2024
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase, from 9:45AM ET on Monday Jun 17, 2024 by Dow Jones
9:45AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 10, 2024
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML, from 8:40AM ET on Monday Jun 10, 2024 by Dow Jones
8:40AM ET on Monday Jun 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sellas Life Sciences Group Inc | 64.7M | -1.1x | --- |
Genenta Science SPA | 61.0M | -4.5x | --- |
Annovis Bio Inc | 64.0M | -1.1x | --- |
Elicio Therapeutics Inc | 66.1M | -0.7x | --- |
Instil Bio Inc | 63.1M | -0.5x | --- |
AN2 Therapeutics Inc | 62.9M | -0.8x | --- |
Company Information
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Contact Information
- Headquarters
- 7 TIMES SQUARE, SUITE 2503NEW YORK, NY, United States 10036
- Phone
- 646-200-5278
- Fax
- 925-498-7799
Executives
- Independent Chairman of the Board
- Jane Wasman
- President, Chief Executive Officer, Director
- Angelos Stergiou
- Chief Financial Officer
- John Burns
- Senior Vice President - Clinical Development
- Dragan Cicic
- Vice President - Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality
- Andrew Elnatan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $64.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.40 |
EPS | $-1.12 |
Book Value | $-0.25 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
